What is GSM — and why does the name matter?
GSM — genitourinary syndrome of menopause — is the term that replaced "vaginal atrophy," and the change was deliberate.
In 2014, two major medical organizations formally retired the older label and adopted GSM instead.11 The reasons were practical: "vaginal atrophy" missed the urinary half of the picture (urgency, leaking, recurrent infections), and it carried a stigmatizing ring that made the subject even harder for women and doctors to raise. GSM is more precise and more complete. It names a syndrome — a cluster of related changes — not just a tissue change in one place.
The cluster includes: vaginal dryness, burning, and irritation; pain or discomfort during sex; a narrowing of the vaginal opening over time; urinary urgency and frequency; and a higher rate of urinary tract infections. These are not separate problems — they share a single cause.
What is actually happening to the tissue?
Estrogen loss changes the tissue in the vagina, vulva, and lower urinary tract in a cascade of ways, each feeding the next.
The cells lining the vaginal walls thin out. They produce less lubrication. The tissue loses its natural folds and suppleness. Vaginal pH rises — becoming less acidic — which shifts the local bacterial environment away from the protective lactobacilli that normally dominate it. That shift makes irritation and infection more likely.
One consequence matters more than most people realize: unlike hot flashes, which typically ease on their own over time, GSM is progressive. If you don't treat it, it continues to worsen. A visit to a gynecologist six years after menopause found GSM in 84% of women examined.22 The tissue changes are also why intercourse becomes painful for so many women — friction against dry, thinned tissue causes tears and inflammation that can persist for days.
None of this is inevitable, but it does not self-correct.
How common is this — and why don't more women get help?
GSM is one of the most common consequences of menopause, affecting somewhere between 27% and 84% of postmenopausal women depending on how it is measured and when.22
Despite those numbers, most women never bring it up with a provider — and many providers don't ask. The reasons are layered: embarrassment, a belief that it is just part of getting older, a worry about being dismissed, or simply not having language for what is happening. Many women quietly withdraw from sex, or grit through it, for years.
The silence matters clinically because GSM does not resolve on its own. Every year without treatment is a year of progression. This is one area where speaking up, or having a provider who asks directly, makes a real difference.
What actually treats it?
Treatment works. The approach depends on how much GSM is affecting your life.
For mild symptoms: Long-acting vaginal moisturizers used regularly (not just during sex) are the first step. They restore surface moisture and help normalize pH. For sex specifically, a good lubricant — water-based or silicone-based — makes an immediate difference. Avoid scented, flavored, or "warming" products; they irritate already-sensitive tissue.22
For moderate-to-severe symptoms: This is where prescription options come in, and all of the following have solid evidence behind them.22
- Low-dose vaginal estrogen — available as a cream, tablet, soft-gel insert, or ring — works directly at the tissue level and has a well-established evidence base for relieving GSM symptoms.44 Because the dose is local and low, it does not meaningfully raise estrogen levels in the bloodstream above normal postmenopausal ranges at standard dosing.55 You do not need to take a progestogen alongside it (unlike systemic hormone therapy) because it is not absorbed at levels that affect the uterine lining.22
- Vaginal DHEA (prasterone) — a vaginal insert that converts locally to both estrogen and testosterone in the tissue. FDA-approved for painful sex caused by GSM.
- Ospemifene — an oral pill taken daily, in the family of medications called SERMs (selective estrogen receptor modulators). FDA-approved for dyspareunia (painful sex) caused by GSM. A useful option if you prefer not to use anything vaginally.
- Systemic hormone therapy — if you are already using HT to treat hot flashes or other symptoms, it also treats GSM, though some women still need a local vaginal product on top of it.
What about lasers? CO₂ and Er:YAG vaginal laser devices are marketed aggressively for GSM. NAMS's 2020 position is that the evidence from properly controlled trials is insufficient to recommend them, and the FDA has issued a safety communication about unapproved marketing of these devices for vaginal use.22 They may have a future role, but the current evidence bar has not been cleared.
Is vaginal estrogen actually safe?
For the large majority of women, yes — and the packaging may be misleading you.
Low-dose vaginal estrogen carries an FDA boxed warning inherited from systemic hormone therapy studies — the same warning language appears on a cream used for a hot flash and on a vaginal insert absorbed only locally. The two are not the same thing.33 Multiple medical societies, including NAMS, have argued that the boxed warning should not apply to low-dose vaginal products because systemic absorption at standard doses is minimal.2233
For women who have had breast cancer, vaginal estrogen is a more complex discussion and should be coordinated with the oncology team. For most other women without contraindications, the data support using it with appropriate medical guidance.
The more important point: the fear of a warning label is keeping many women in unnecessary pain and away from a treatment with strong evidence and a well-characterized safety record going back decades.